Total Extract of Averrhoa Carambola L. (Oxalidaceae) Roots Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Rats
Description
Figure 1: Effect of EACR on organ index (Ⅰ: normal control group, Ⅱ: 50% CCl4 model group, Ⅲ: 0.2 mg/kg colchicine+50% CCl4, Ⅳ: 1.0 g/kg EACR+50% CCl4, Ⅴ: 0.5 g/kg EACR+50% CCl4, Ⅵ: 0.25 g/kg EACR+50% CCl4). Results are presented as the mean ± S.D (n = 10). *P<0.05 or **P<0.01 as compared with normal control group, #P<0.05 or ##P<0.01 as compared with the CCl4 model group. Figure 2: Effect of EACR on the levels of ALT, AST, AKP and Hyp (Ⅰ: normal control group, Ⅱ: 50% CCl4 model group, Ⅲ: 0.2 mg/kg colchicine+50%CCl4, Ⅳ: 1.0 g/kg EACR+50% CCl4, Ⅴ: 0.5g/kg EACR+50%CCl4, Ⅵ: 0.25 g/kg EACR+50% CCl4). Results are presented as the mean ± S.D (n = 10). *P<0.05 or **P<0.01 as compared with normal control group, #P<0.05 or ##P<0.01 as compared with the CCl4 model group. Figure 3: Effect of EACR on levels of HA, LN, ColⅢ, ColⅣ(Ⅰ: normal control group, Ⅱ: 50% CCl4 model group, Ⅲ: 0.2 mg/kg colchicine+50% CCl4, Ⅳ: 1.0 g/kg EACR+50% CCl4, Ⅴ: 0.5 g/kg EACR+50% CCl4, Ⅵ: 0.25 g/kg EACR+50% CCl4). Results are presented as the mean ± S.D (n = 10). *P<0.05 or **P<0.01 as compared with normal control group, #P<0.05 or ##P<0.01 as compared with the CCl4 model group. Figure 4: Effect of EACR on levels of SOD, MDA, GSH, GSH-Px (Ⅰ: normal control group, Ⅱ: 50% CCl4 model group, Ⅲ: 0.2 mg/kg colchicine+50% CCl4, Ⅳ: 1.0 g/kg EACR+50% CCl4, Ⅴ: 0.5 g/kg EACR+50% CCl4, Ⅵ: 0.25 g/kg EACR+50% CCl4). Results are presented as the mean ± S.D (n = 10). *P<0.05 or **P<0.01 as compared with normal control group, #P<0.05 or ##P<0.01 as compared with the CCl4 model group. Figure 5: Representative histopathological images of the liver specimens in different experimental groups stained with hematoxylin and eosin (Fig. 6 A, ×200). GroupⅠ: normal control group showed normal cellular structure. GroupⅡ: 50% CCl4 model group, showed marked pathological changes, hepatocytes and inflammation. Treatment with colchicine or EACR ameliorated the severity of CCl4-induced liver fibrosis ( GroupⅢ: 0.2 mg/kg colchicine+50% CCl4, Ⅳ: 1.0 g/kg EACR+50% CCl4, Ⅴ: 0.5 g/kg EACR+50% CCl4, Ⅵ: 0.25 g/kg EACR+50% CCl4). Representative Masson’s trichrome staining images showing collagen deposition in rat liver tissue(Fig. 6 B, ×200). GroupⅠ: normal control group showed traces of collagen only in the walls of major blood vessels. GroupⅡ: 50% CCl4 model group, resulted in extensive accumulation of collagen in the liver tissue. Treatment with colchicine or EACR markedly reduced collagen production and deposition ( GroupⅢ:.0.2 mg/kg colchicine+50% CCl4, Ⅳ:.1.0 g/kg EACR+50% CCl4, Ⅴ:.0.5 g/kg EACR+50% CCl4, Ⅵ:.0.25 g/kg EACR+50% CCl4). Figure 6: Effect of EACR on the expressions ofα-SMA, Col-1a1, TGF-β1, Smad2, Smad4, Smad7, TIMP-1, TIMP-2mRNA (Ⅰ: normal control group, Ⅱ: 50% CCl4 model group, Ⅲ: 0.2 mg/kg colchicine+50% CCl4, Ⅳ: 1.0 g/kg EACR+50% CCl4, Ⅴ:0.5 g/kg EACR+50% CCl4, Ⅵ: 0.25 g/kg EACR+50% CCl4). Results are presented as the mean ± S.D (n = 3). *P<0.05 or **P<0.01 as compared with normal control group,